Bill Text: IL HB2346 | 2025-2026 | 104th General Assembly | Introduced

---

Bill Title: Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department".

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced) 2025-02-04 - Referred to Rules Committee [HB2346 Detail]

Download: Illinois-2025-HB2346-Introduced.html

---

104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2346 Introduced , by Rep. Laura Faver Dias SYNOPSIS AS INTRODUCED:
410 ILCS 715/5
410 ILCS 715/45
410 ILCS 715/55
410 ILCS 715/70 new
Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department".
LRB104 06540 BDA 16576 b
A BILL FOR
HB2346 LRB104 06540 BDA 16576 b
AN ACT concerning health.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Drug Reuse Opportunity Program Act
is amended by changing Sections 5, 45, 55, and 70 as follows:
(410 ILCS 715/5)
Sec. 5. Definitions. In this Act:
"Controlled substance" means a drug, substance, or
immediate precursor in Schedules I through V of 21 CFR 1308.
"Department" means the Illinois Department of Public
Health.
"Dispense" has the same meaning as defined in Section 3 of
the Pharmacy Practice Act.
"Donor" means any person, including an individual member
of the public, or any entity legally authorized to possess
medicine, including, but not limited to, a wholesaler or
distributor, third party logistic provider, pharmacy,
dispenser, clinic, surgical or health center, detention and
rehabilitation center, jail, prison laboratory, medical or
pharmacy school, prescriber or other health care professional,
long-term care facility, or healthcare facility. "Donor"
includes government agencies and entities that are federally
authorized to possess medicine, including, but not limited to,

HB2346 - 2 - LRB104 06540 BDA 16576 b
drug manufacturers, repackagers, relabelers, outsourcing
facilities, health care facilities operated by the U.S.
Department of Veterans Affairs, and prisons.
"Drug" means a prescription drug, over-the-counter drug,
or supplies needed to administer a prescription or
over-the-counter drug.
"Eligible patient" means an individual:
(1) with a prescription for the drug, if a
prescription is required to dispense the drug, or who
reports symptoms treated by the drug if the drug is
over-the-counter; and
(2) who is registered with the drug's manufacturer in
accordance with federal Food and Drug Administration
requirements, if the registration is required to dispense
the drug.
"Manufacturer" has the same meaning as defined in Section
15 of the Wholesale Drug Distribution Licensing Act.
"Pharmacist" means an individual licensed to engage in the
practice of pharmacy under the Pharmacy Practice Act or
licensed to engage in the practice of pharmacy in another
state.
"Practitioner" means a person licensed in this State to
dispense or administer drugs or who is licensed in another
state as a person authorized to dispense or administer drugs.
"Prescription drug" means any prescribed drug that may be
legally dispensed by a pharmacy. "Prescription drug" does not

HB2346 - 3 - LRB104 06540 BDA 16576 b
include a drug for the treatment of cancer that can only be
dispensed to a patient registered with the drug manufacturer
in accordance with the federal Food and Drug Administration's
requirements.
"Priority patient" means an eligible patient who is an
Illinois resident and who is indigent, uninsured,
underinsured, or enrolled in a public health benefits program.
"Recipient" means any person or entity legally authorized
to possess medicine with a license or permit in the state in
which the person or entity is located, including, but not
limited to, a wholesaler or distributor, reverse distributor,
repackager, hospital, pharmacy, or clinic.
"Returns processor" has the same meaning as defined in
paragraph (18) of 21 U.S.C. 360eee. "Returns processor"
includes, but is not limited to, a reverse distributor.
"Unopened tamper-evident packaging" has the same meaning
as defined in the United States Pharmacopeia (USP) General
Chapter 659, Packaging and Storage Requirements, including,
but not limited to, unopened unit-dose, multiple-dose,
immediate, secondary, and tertiary packaging.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/45)
Sec. 45. Recordkeeping requirements. When performing any
action associated with a program under this Act or otherwise
processing a donated drug for tax, manufacturer, or other

HB2346 - 4 - LRB104 06540 BDA 16576 b
credit, a recipient shall be considered to be acting as a
returns processor and shall comply with all recordkeeping
requirements for nonsalable nonsaleable returns under federal
law. Records maintained under this Act may be accessed by the
Department upon request.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/55)
Sec. 55. Retention of records. All records required under
this Act shall be retained in physical or electronic format
and on or off the recipient's premises for a period of 6 years.
Donors or recipients may contract with one another or a third
party to create or maintain records on each other's behalf. An
identifier, such as a serial number or bar code, may be used in
place of any or all information required by a record or label
pursuant to this Act if it allows for such information to be
readily retrievable. Upon request by a State or federal
regulatory agency, the identifier used for requested records
shall be replaced with the original information. An identifier
shall not be used on patient labels when dispensing or
administering a drug. Records maintained under this Act may be
accessed by the Department upon request.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/70 new)
Sec. 70. Program support provided by the Department. The

HB2346 - 5 - LRB104 06540 BDA 16576 b
Department shall:
(1) develop, maintain, and publish on its website
information regarding the names and locations of
pharmacies participating in the program;
(2) educate pharmacies in the State about the program
and how to participate in it voluntarily;
(3) develop and publish educational materials to allow
program participants and the Department to inform the
general public about the purposes and benefits of the
program; and
(4) collect information from participants and publish
the information in an annual report to the General
Assembly by December 31 of each calendar year, beginning
December 31, 2026.